Company / Current Liabilities
Apellis Pharmaceuticals, Inc. Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$323.6M
FY2025
5-year range
$131.8M / $323.6M
FY2021-FY2025
Trend
+74.4%
vs FY2024
Sector context
#43 of 213
Health Care
What the data says
Apellis Pharmaceuticals, Inc.'s current liabilities of $324M is higher than 80% of companies in the Health Care sector (FY2025). Increased from $248M to $324M over the past 2 years.
Based on SEC 10-K filings.
$324M in FY2025 with a 5-year CAGR of +20.3%. Top quartile in the Health Care sector.
Increased from $248M to $324M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +24.5%
- 5-Year CAGR
- +20.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 20% in Health CareTop 80% of 213This company $323.6M Sector average $1.6B
▼
-79.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +20.3%, indicating consistent growth.
- In FY2025, current liabilities increased 74.4% year-over-year.
- Ranks #43 out of 213 companies in the Health Care sector.
- Lowest current liabilities in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $323.6M | +74.4% |
| FY2024 | $185.5M | -25.1% |
| FY2023 | $247.6M | +47.7% |
| FY2022 | $167.6M | +27.1% |
| FY2021 | $131.8M | +2.7% |
| FY2020 | $128.3M | +95.2% |
| FY2019 | $65.8M | +286.2% |
| FY2018 | $17.0M | +159.8% |
| FY2017 | $6.6M | +80.1% |
| FY2016 | $3.6M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026